Documents
A list of downloadable documents created during development.
Breast cancer (advanced or metastatic) - lapatinib: second appeal
-
Breast cancer (advanced or metastatic) - lapatinib: appeal decision
-
Appeal received
-
Initial scrutiny letter
-
Response to scrutiny letter
-
Final scrutiny letter
Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination
-
Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination
-
Response to consultee, commentator and public comments on the appraisal consultation document (ACD 3)
-
Consultee and commentator comments on the ACD
-
GlaxoSmithKline
-
Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support
-
Royal College of Nursing
-
The Royal College of Pathologists
-
NCRI Breast Clinical Studies Group/RCP/RCR/ACP/JCCO
-
Department of Health
-
Welsh Assembly Government
-
Roche
-
Letter to consultees and commentators
-
Letter to Guidance Executive - prepared by Professor Philip Home (Vice-Chair of Committee)
Breast cancer (advanced or metastatic) - lapatinib: (2nd line) paper - post GE January 2010
-
Breast cancer (advanced or metastatic) - lapatinib: (2nd line) paper - post GE January 2010
Breast cancer (advanced or metastatic) - lapatinib: appraisal consultation document
-
Evaluation report
-
Appraising life - extending, end of life treatments paper
-
Report by the Decision Support Unit
-
Breast cancer (advanced or metastatic) - lapatinib: appeal decision
-
Non-manufacturer submissions
-
Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support
-
Royal College of Nursing
-
Royal College of Physicians
-
Roche
-
GlaxoSmithKline (including clarification required from NICE)
-
Final submission
-
Responses to DSU questions
Breast cancer (advanced or metastatic) - lapatinib: appeal
-
Appeals received
-
Initial scrutiny letter
-
Response to scrutiny letter
-
Final scrutiny letter
-
Clarification letter from appellant
-
Response to clarification letter
-
Breast cancer (advanced or metastatic) - lapatinib: appeal decision
Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination
-
Breast cancer (advanced or metastatic) - lapatinib: final appraisal determination
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
Response and comments to the website consultation on the Appraisal Consultation Document - prepared by the technical lead
-
Response to consultee and commentator comments on the Appraisal Consultation Document - prepared by the technical lead
-
Consultee and commentator comments on the ACD
-
Breakthrough Breast Cancer
-
Department of Health
-
GlaxoSmithKline - 1
-
GlaxoSmithKline - 2
-
National Collaborating Centre for Cancer
-
Royal College of Nursing
-
Royal College of Physicians
-
Roche
-
Expert comments on the ACD
-
Carolyn Rogers
-
Justin Stebbing
Breast cancer (advanced or metastatic) - lapatinib (appraisal consultation 2)
-
Breast cancer (advanced or metastatic) - lapatinib: evaluation report
-
Non-manufacturer submissions
-
Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care, and Macmillian Cancer Support (joint submission)
-
Breast Cancer Care supporting letter
-
Department of Health (2)
-
National Collaborating Centre for Cancer
-
Roche
-
Royal College of Nursing
-
Royal College of Physicians
-
Royal College of Pathologists
-
Sanofi Aventis
-
Southampton Health Technology Assessment Centre
-
Manufacturer submission
-
GlaxoSmithKline comments on ERG report
-
GlaxoSmithKline response to ACD1
-
GlaxoSmithKline appendices to ACD1
-
GlaxoSmithKline addendum
-
GlaxosmithKline response to clarification letter
-
NICE Clarification letter
-
Decision Support Unit report
-
DSU Report
-
DSU specification form
-
DSU addendum to report
-
Rogers
Breast cancer (advanced or metastatic) - lapatinib (appraisal consultation)
-
Breast cancer (advanced or metastatic) - lapatinib: evaluation report
-
Breast cancer (advanced or metastatic) - lapatinib: Evidence Review Group report
-
Breast cancer (advanced or metastatic) - lapatinib: Non-manufacturer submissions
-
Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care, and Cancerbackup (joint submission)
-
Breast Cancer Campaign supporting letter
-
Breast Cancer Care supporting letter
-
Cancerbackup supporting letter
-
Breast cancer (advanced or metastatic) - lapatinib: Pre-meeting briefing
-
British Association of Surgical Oncology
-
NCRI Breast Group, Joint Collegiate Council for Oncology, Royal College of Radiologists, Association of Clinical Pathologists and Royal College of Physicians (joint submission)
-
Royal College of General Practitioners
-
Royal College of Pathologists
-
GlaxoSmithKline
-
Expert written personal statements
-
Rogers
-
Sinnett
-
Wilby
Update on status of lapatinib for the treatment of previously treated women with advanced, metastatic or recurrent breast cancer
-
Update on status of lapatinib for the treatment of previously treated women with advanced, metastatic or recurrent breast cancer
Breast cancer (advanced or metastatic) - lapatinib: final scope
-
Breast cancer (advanced or metastatic) - lapatinib: final scope
Breast cancer (advanced or metastatic) - lapatinib: response to consultee and commentators comments on the scope
-
Breast cancer (advanced or metastatic) - lapatinib: response to consultee and commentators comments on the scope
Breast cancer (advanced or metastatic) - lapatinib: response to consultee and commentators comments on the matrix
-
Breast cancer (advanced or metastatic) - lapatinib: response to consultee and commentators comments on the matrix
Breast cancer (advanced or metastatic) - lapatinib: pre-referral scope
-
Breast cancer (advanced or metastatic) - lapatinib: pre-referral scope
Breast cancer (advanced or metastatic) - lapatinib: pre-referral matrix
-
Breast cancer (advanced or metastatic) - lapatinib: pre-referral matrix